Alex J. Walker
When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English healthcare data
Walker, Alex J.; West, Joe; Card, Timothy R.; Crooks, Colin J.; Kirwan, Cliona C.; Grainge, Matthew J.
Authors
Professor JOE WEST JOE.WEST@NOTTINGHAM.AC.UK
PROFESSOR OF EPIDEMIOLOGY
Dr TIM CARD tim.card@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR
Dr COLIN CROOKS Colin.Crooks@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR
Cliona C. Kirwan
Dr MATTHEW GRAINGE MATTHEW.GRAINGE@NOTTINGHAM.AC.UK
ASSOCIATE PROFESSOR
Abstract
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. However, no previous epidemiological studies have investigated the relative impact of breast cancer treatments in a time-dependent manner. We aimed to determine the impact of breast cancer stage, biology and treatment on the absolute and relative risks of VTE, using several recently linked data sources from England. Our cohort comprised 13,202 breast cancer patients from the Clinical Practice Research Datalink (linked to Hospital Episode Statistics and Cancer Registry data), diagnosed between 1997 and 2006 with follow-up continuing to the end of 2010. Cox regression analysis was performed to determine which demographic, treatment-related and biological factors independently affected VTE risk. Women had an annual VTE incidence of 6% whilst receiving chemotherapy which was 10.8-fold higher (95% CI, 8.2 to 14.4; absolute risk (AR) =59.6 per 1000 person-years) than women who did not receive chemotherapy. Following surgery the risk was significantly raised in the first month (HR=2.2; 95% CI 1.4 to 3.4; AR=23.5; reference group, no surgery), but it was not raised subsequent to this. Risk of VTE was noticeably higher in the 3-months following initiation of Tamoxifen compared with the risk before therapy (HR=5.5; 95% CI 2.3 to 12.7; AR=24.1), however commencement of aromatase inhibitors was not associated with VTE (HR=0.8; 95% CI 0.5 to 1.4; AR=28.3). In conclusion, women receiving chemotherapy for breast cancer have a clinically important risk of VTE, whilst an increased risk of VTE immediately following endocrine therapy is restricted to Tamoxifen.
Citation
Walker, A. J., West, J., Card, T. R., Crooks, C. J., Kirwan, C. C., & Grainge, M. J. (2015). When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English healthcare data. Blood, 127(7), 849-857. https://doi.org/10.1182/blood-2015-01-625582
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 3, 2015 |
Online Publication Date | Feb 18, 2016 |
Publication Date | Nov 16, 2015 |
Deposit Date | Jan 15, 2016 |
Publicly Available Date | Jan 15, 2016 |
Journal | Blood |
Print ISSN | 0006-4971 |
Electronic ISSN | 1528-0020 |
Publisher | American Society of Hematology |
Peer Reviewed | Peer Reviewed |
Volume | 127 |
Issue | 7 |
Pages | 849-857 |
DOI | https://doi.org/10.1182/blood-2015-01-625582 |
Keywords | deep vein thrombosis, pulmonary embolism, breast cancer, chemotherapy, surgery, Tamoxifen, cohort study, Clinical Practice Research Datalink |
Public URL | https://nottingham-repository.worktribe.com/output/766681 |
Publisher URL | http://www.bloodjournal.org/content/early/2015/11/16/blood-2015-01-625582 |
Files
Blood 2015 Walker et al..pdf
(938 Kb)
PDF
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search